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Anti-vascular endothelial growth factor (anti-VEGF) therapies have  
revolutionized the care of patients with retinal diseases. In the 1990s, it was 
observed that anti-VEGF antibodies reduced tumor angiogenesis, and conse-
quently, these antibodies started to be used off-label in the exudative form of 
age-related macular degeneration (AMD). In the 2000s, research was directed 
towards the development of anti-VEGF therapies for retinal disease management. 
Several anti-VEGF therapies were approved: pegaptanib, an RNA aptamer, in 
2004; ranibizumab, an anti-VEGF Fab, in 2008; aflibercept, a humanized IgG Fc, 
in 2011; and brolucizumab, an scFv, in 2019. Currently, new therapeutic options 
are emerging, and approval is expected soon. These new therapies aim to increase 
treatment durability and thus reduce treatment burden and improve real-world 
outcomes. In this chapter, the mechanisms of action and the preliminary trial 
results of these potential new therapies will be described.
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1. Introduction
Global prevalence estimates suggest that approximately 196 million people 
lived with age-related macular degeneration (AMD) in 2020. Of these, 10.4 million 
people were living with moderate to severe vision impairment. In 2030, AMD is 
estimated to affect 243 million people due to aging [1]. The pathogenesis of AMD 
results from complex multifactorial interactions, including metabolic, genetic, and 
environmental [2]. AMD has been classified into two major subtypes: non-exuda-
tive or dry AMD and exudative or wet AMD. Although dry AMD represents 90% of 
patients, exudative AMD causes more severe loss of vision, being the target of most 
investigations [3]. These patients require very regular clinic visits, and the chronic-
ity of anti-vascular endothelial growth factor (anti-VEGF) therapy can substan-
tially impact the quality of life of the patient and the caregivers [4, 5]. This decrease 
can compromise anti-VEGF therapy compliance and explain the undertreatment 
of patients observed in real-world studies and the waiver of patients involved in 
clinical trials [6, 7]. New trials are focusing on improving the therapeutic options, 
particularly on the decrease of the associated burden. This chapter describes the 
current research on therapeutical approaches to treat the dry and exudative forms 
of AMD. Figure 1 summarizes the drugs and stages of development.
The information was gathered from a medical literature review and ongoing 
clinical trials and their results in the area of AMD treatment using PubMed data-
base (https://www.ncbi.nlm.nih.gov/pubmed). The words or medical head subjects 
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used were: AMD and clinical trials. All relevant articles were imported into Zotero 
(Version 5.0, Center for History and New Media at Universidade George Mason, 
USA), and duplicate articles were deleted. We selected the promising therapies 
according to action mechanisms and excluded all therapies that had failed in clinical 
trials. Comments, editorials, and articles not written in English were not analyzed.
2. For dry AMD
2.1 Complement inhibition
Although lampalizumab (anti-factor D Fab) and eculizumab (inhibitor of the 
activation of terminal complement) failed to slow geographic atrophy progression, 
the complement system has been implicated in the pathogenesis of geographic atro-
phy, and so, research on how to inhibit the complement system did not stop [8, 9].
Pegcetacoplan (APL-2; Apellis Pharmaceuticals, Waltham, Massachusetts, USA) 
is a synthetic molecule that selectively inhibits C3, effectively downregulating all 
three complement pathways. Phase 2 of the FILLY clinical trial compared patients 
receiving intravitreal injection (monthly and bi-monthly) with a control group. 
The results showed a 29% reduction in the rate of geographic atrophy and a better 
outcome in the monthly injection group. Moreover, it was observed that the risk of 
neovascular AMD was higher (18%) in the group subjected to monthly injections 
when comparing with the group subjected to bi-monthly injections (8%) and with 
the control group (1%) [10]. A phase 3 trial is currently in the recruitment phase 
(NCT03525600) [11].
Avacincaptad pegol (Zimura; Iveric Bio, New York, New York, USA) is a C5 
inhibitor. Phase 2/3 GATHER1 clinical trial showed a significant reduction of geo-
graphic atrophy growth over 12 months, probably due to C3 activity preservation. A 
second confirmatory trial (GATHER2) is underway [12].
2.2 Neuroprotection
Retinal neuroprotection strategies have been studied for dry AMD, including 
apoptosis and necrosis prevention, and oxidative injury reduction [13].
Figure 1. 
Summary of new drugs in the pipeline for the management of age-related macular degeneration (AMD).
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Elamipretide (Stealth Biotherapeutics) is a mitochondria-targeted drug thought 
to reduce mitochondrial dysfunction. Phase 1 of the ReCLAIM clinical trial showed 
that elamipretide was safe, well-tolerated and that this drug may improve vision 
in patients with intermediate AMD, manifested as high-risk drusen [14]. Phase 2 
ReCLAIM-2 clinical trial is underway [15].
Brimonidine tartrate (Allergan) is best known in glaucoma as the intraocular 
pressure (IOP) lowering agent. Phase 2A of the BEACON clinical trial assessed the 
intravitreally delivery of brimonidine through a delayed delivery system. Results 
showed a lower rate of geographic atrophy progression, although not statistically 
significant [16]. Phase 2B of the BEACON clinical trial demonstrated a reduction in 
geographic atrophy progression using higher doses of brimonidine [17]. Phase 3 of 
IMAGINE and ENVISION clinical trials are being designed [16].
2.3 Visual cycle modulators
One of the earliest changes in the retina that precede AMD symptoms is the 
formation of toxic vitamin A dimers.
ALK-001 (Alkeus Pharmaceuticals) is a chemically modified form of vitamin 
A that replaces the vitamin A in the body to prevent toxic vitamin A dimers. 
Studies demonstrated functional preservation of visual function in animal 
models [18]. Phase 3 of the SAGA clinical trial will measure the extent to which 
treatment with the oral capsule of ALK-001 slows geographic atrophy  
progression [19].
2.4 Cell-based therapies
Cell therapy is an alternative strategy when the naturally existing cells are 
already too damaged to be preserved using neuroprotective agents. Human plu-
ripotent stem cells (hPSCs) comprise human embryonic stem cells (hESCs) and 
human-induced pluripotent stem cells (hiPSCs). There are two subtypes of cell-
based treatments: stem cell therapies that involve delivering new retinal pigment 
epithelial (RPE) cells to the subretinal space, and non-stem cell therapies based on 
cell implantation, which generates protective factors [20].
MA09-hRPE (Astellas Pharma) is hESC-derived Retinal Pigment Epithelium 
(hESC-RPE). The phases 1/2 clinical trial results confirmed that hESC-derived 
cells could serve as a potentially safe new source for regenerative medicine [21–23].
CPCB-RPE1 (The California Project to Cure Blindness-Retinal Pigment 
Epithelium1) is a polarized monolayer of hESC-RPE ultrathin, synthetic parylene 
substrate designed to mimic Bruch’s membrane. This therapy involves a subretinal 
implant. It was demonstrated the feasibility and safety of CPCB-RPE1 subretinal 
implantation in a comparable animal model [24]. Phase 1/2A of the clinical trial 
suggests that CPCB-RPE1 may improve visual function [25, 26].
2.5 Anti-inflammatory agents
Inflammation has been implicated in AMD pathogenesis and progression, even 
though it is no classical inflammatory disease like uveitis [27].
Doxycycline (Oracea; Galderma Laboratories, Fort Worth, Texas, USA) is 
an antibiotic that belongs to the tetracycline class of antibiotics and plays a role 
in immunomodulation, cell proliferation, angiogenesis, and the regulation of 
inflammation. Phase 3 of the TOGA clinical trial includes patients with geographic 
atrophy randomized in groups treated with Oracea® or placebo. The results are 
pending [28].
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FHTR2163 (Genentech/Roche) is a new antibody delivered by intravitreal 
injection that inhibits the HTRA1 gene associated with geographic atrophy. Phase 2 
of the GALLEGO clinical trial will evaluate the safety, tolerability, and efficacy of 
intravitreal injections of RG6147, administered every four or every eight weeks for a 
total of approximately 76 weeks, in participants with geographic atrophy secondary 
to AMD (when compared with the sham control) [29].
3. For wet AMD
3.1 Potentially more durable anti-VEGF agents
Potentially more durable anti-VEGF agents may reduce the burden of intravit-
real injections, help stabilize the disease and improve compliance with treatment.
Brolucizumab (Beovu; Novartis, Basel, Switzerland) is the most recent intra-
vitreal anti-VEGF agent to receive FDA approval. It is a humanized single-chain 
antibody fragment with a molecular weight of 26 kDa. Phase 3 of the HAWK and 
HARRIER clinical trials showed that brolucizumab was non-inferior to aflibercept 
regarding visual function as at week 48, more than 50% of the eyes treated with 
6 mg of brolucizumab were maintained on q12w dosing intervals. Moreover, 
anatomic outcomes favored brolucizumab over aflibercept, and the overall safety 
results were similar between the two drugs [30].
Abicipar pegol (Allergan) is a novel class of molecules referred to as designed 
ankyrin repeat proteins (DARPin) that bind VEGF-A. DARPin is smaller and has 
a high affinity to VEGF, leading to greater stability and a longer-acting effect. The 
results of phase 3 of the SEQUOIA and CEDAR clinical trials showed that the eight 
and 12-week abicipar regimens were non-inferior to the ranibizumab’s monthly 
regimen, but patients had a much higher risk of developing intraocular inflamma-
tion (15% and 15.4% vs. 0%) [31–33]. The company modified the manufacturing 
process after finding impurities in the formulation, and subsequently, the MAPLE 
study showed a decrease in the incidence of intraocular inflammation to 8.9% 
[34]. A license for abicipar pegol was already submitted to the Food and Drug 
Administration and the European Medicines Agency.
Conbercept (Chengdu Kanghong Biotech Co., Ltd.) is an antibody that targets 
VEGF-A, VEGFB, VEGF-C, and placental growth factors. It was approved to treat 
exudative AMD in China in 2013. Phase 2 of the AURORA and phase 3 of the 
PHOENIX clinical trials showed the safety and efficacy of conbercept with three 
initial monthly treatments followed by quarterly treatments compared with the 
sham group [35, 36]. Phase 3 of the PANDA-1 and PANDA-2 global clinical tri-
als compare maintenance doses of conbercept every 8 or 12 weeks with doses of 
aflibercept every eight weeks; results are expected in 2022 [37, 38].
OPT-302 (Opthea Limited) is a soluble form of the human VEGF recep-
tor-3 (VEGFR-3), expressed as an Fc-fusion protein molecule design to inhibit 
VEGF-C and VEGF-D. Results from phases 1 and 2 of the ShORe and COAST 
clinical trials showed that this molecule was safer and had better visual out-
comes than ranibizumab alone [39, 40]. Phase 3 of the ShORe and COAST clini-
cal trials will be double-masked and sham-controlled. Treatment-naïve patients 
will be enrolled to assess the efficacy and safety of 2.0 mg OPT-302 combined 
with anti-VEGF-A therapy by comparison with anti-VEGF-A monotherapy 
(standard of care). Opthea expects to initiate patient recruitment in the first 
half of 2021 [41].
Faricimab (Roche, Genentech) is a novel bispecific antibody that targets both 
angiopoietin-2 (Ang-2) and VEGF-A. Phase 2 of the STAIRWAY clinical trial 
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suggests that faricimab can be an effective maintenance therapy for exudative AMD 
with a dosing interval of 16 weeks [42, 43]. Phase 3 of the TANAYA and LUCERNE 
clinical trials will compare faricimab given every 16 weeks with aflibercept given 
every eight weeks [44, 45]. FDA requests for faricimab are expected to occur in 2021 
for diabetic macular edema and in 2022 for exudative AMD.
KSI-301 (Kodiak Sciences) is a novel intravitreal, anti-VEGF antibody biopoly-
mer conjugate designed to block all VEGF-A isoforms. Phase 1 of the DAZZLE 
clinical trial showed excellent safety, strong efficacy, and considerable durability in 
most patients for three or more months [46]. Phase 2 of the DAZZLE clinical trial 
is a prospective, randomized controlled clinical trial designed to evaluate the safety 
and efficacy of KSI-301 [47].
3.2 ONS-5010 and biosimilars
ONS-5010 (Outlook Therapeutics, Inc) is an ophthalmic formulation of 
bevacizumab. Phase 3 clinical trials compare monthly doses of ONS-5010 with a 
ranibizumab regimen of 3 monthly doses followed by quarterly doses [48]. FDA 
approval is expected in 2021 or 2022, and 12 years of exclusivity, protecting against 
bevacizumab biosimilars, are expected.
FYB201 (Formycon and Bioeq), SB11 (Samsung Bioepis), and Xlucane 
(Xbrane Biopharma) are biosimilars for ranibizumab under development that 
are expected to reach the market in less than one year when the patent for ranibi-
zumab expires [49–51].
Aflibercept biosimilars are in phase 3 of clinical trials and are expected to reach 
the market between two and three years when the patent for aflibercept expires.
3.3 Topical anti-VEGF ± anti-PDGF
Although regorafenib, pazopanib, and LHA510 failed, other therapies showed 
promising results [52–54]. These formulations have the great advantage of being 
less invasive, but they can decrease the possibility of monitoring treatment compli-
ance, as it happens with glaucoma patients medicated with lowering ocular hyper-
tension drops.
PAN-90806 (PanOptica) is a topical formulation of a small molecule, a tyrosine 
kinase inhibitor (TKI), to treat wet AMD. In phase 1/2 of a dose-ranging clinical 
trial, more than half of patients receiving PAN-90806 once a day for 12 weeks 
completed the study without needing anti-VEGF rescue therapy. Fourteen of the 51 
patients in the study, 88% experienced clinical improvement of their condition or 
their disease’s stability [55].
Squalamine lactate (Genaera Corporation) is an amino sterol derived from 
the dogfish shark’s cartilage that blocks VEGF, PDGF basic fibroblast growth 
binding calmodulin and its chaperones. A phase 2 clinical trial showed improved 
vision when squalamine lactate was used in combination with anti-VEGF  
treatments [56, 57].
3.4 Extended-release options
The extended-release options may also reduce the burden of intravitreal 
injections.
The port delivery system (PDS; Hoffmann-La Roche) is a permanent, refill-
able implant, which is surgically placed at the pars plana through an incision in the 
sclera. PDS continuously releases concentrated ranibizumab by passive diffusion 
into the vitreous cavity.
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Phase 2 of the LADDER clinical trial showed similar functional and anatomical 
outcomes after nine months of treatment with ranibizumab delivered through PDS 
or monthly intravitreal injections of ranibizumab [58, 59]. The mean time for the 
first PDS refill was 15 months, with 80% of patients not requiring a PDS refill for 
six or more months. Phase 3 of the ARCHWAY clinical trial is ongoing [60].
GB-102 (Graybug Vision) is a depot formulation of sunitinib malate that might 
need only 2 or 3 treatments per year [61]. Phase 2 of the ALTISSIMO clinical trial 
evaluated the safety and effect duration of GB-102 intravitreal injections adminis-
tered every six months compared to aflibercept intravitreal injections administered 
every two months [62]. The results are currently pending.
NT-503 (Neurotech Pharmaceuticals) is a biological sustained drug delivery 
device that can provide anti-VEGF therapy’s continuous delivery. Preliminary 
studies show that the device can be implanted safely in humans [63]. The results of 
phases 1 and 2 of clinical trials are pending [64].
Aflibercept Hydrogel Depot (Regeneron Pharmaceuticals and Ocular 
Therapeutix™) is a delivery system based on a PolyActive hydrogel copolymer’s 
microparticles. In studies with animals intravitreally injected with aflibercept 
hydrogel depot a, sustained and controlled release of aflibercept was achieved. 
No adverse effects in the eyes of healthy rhesus macaques were observed for up to 
6 months [65].
pSivida Durasert Technology (EyePoint Pharmaceuticals, Inc.) can be used to deliver 
different drugs for extended periods (months or even years) with a single application. 
Delivery of a tyrosine kinase inhibitor in animals provided promising results [66].
3.5 Gene therapy
Gene therapy is based on the insertion of an anti-VEGF coding sequence into 
retinal cells’ DNA through a viral vector.
ADVM-022 (Adverum) produces an anti-VEGF-A fusion protein delivered 
through intravitreal injection via the AAV.7 m8 viral vector. Phase 1 of the OPTIC 
clinical trial showed that treatment with a single injection prevented additional 
anti-VEGF treatment over six months [67, 68].
RGX-314 (RegenexBio) (Rockville, MA, USA) produces an anti-VEGF A fab 
delivered through a subretinal treatment via an AAV8 viral vector. Phases 1/2a of 
the AAVIATE clinical trial showed a decrease in injection burden without signifi-
cant inflammation or adverse effects [69]. Phase 2b of the AAVIATE clinical trial 
will explore a suprachoroidal injection [70].
Retinostat (Oxford BioMedica) is a lentiviral vector expressing endostatin and 
angiostatin to inhibit angiogenesis potentially. Phase 1 clinical trial showed that the 
LentiVector® gene therapy platform safely and efficiently delivered genes to the 
retina resulting in stable, long-term expression [71].
AAV2-sFLT01 (Genzyme, a Sanofi Company) is a vector that expresses a modi-
fied soluble Flt1 receptor designed to neutralize the proangiogenic activities of 
VEGF via an intravitreal injection. Phase 1 clinical trial showed that AAV2-sFLT01 
was safe and that there was good tolerance to this vector [72]. After three years of 
follow-up, AAV2-sFLT01 appears to be generally safe, well-tolerated and does not 
appear to raise any new safety concerns [73].
AAVCAGsCD59 (Hemera Biosciences) is a molecule that targets the terminal 
step of complement activation that leads to the formation of the membrane attack 
complex. Two-phase 1 clinical trials for both exudative and dry AMD showed 
that subretinal injection of AAV-CD59 attenuated the formation of laser-induced 
choroidal neovascularization by around 60% in mice, even when the site of delivery 
was distal to the laser-induced choroidal neovascularization site [74].
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An alternative for genetic interference is small interfering RNA (siRNA) that 
inhibits the protein-coding genes and prevent protein synthesis. Delivery can be 
by the topical installation or intravitreal injection. Bevasiranib (Opko) was the 
first siRNA used, but it did not show efficacy in phase 3 of the COBALT clinical 
trial [75]. AGN211745 (Alergan) was designed to reduce pathologic angiogenesis 
mediated by both VEGF and PIG. The study was terminated early due to a company 
decision (non-safety-related), and for this reason, certain outcome measures were 
not analyzed [76].
PF-655 (Pfizer) is a siRNA that inhibits expression of the hypoxia-inducible 
gene RTP801, which inhibits the mammalian target of the rapamycin (mTOR) 
signaling pathway and reduces VEGF-A production. Results from phase 2 of the 
MONET clinical trial showed that the combination of PF-655 with ranibizumab led 
to an average gain in visual acuity superior to the one observed for patients under 
ranibizumab monotherapy [77].
4. Conclusion
There are many potential therapeutic options for AMD. New treatment options 
for dry AMD that slow disease progression or re-establish retinal cells are becoming 
a reality. For wet AMD, new drugs that could lead to a longer half-life in the vitreous, 
lower costs, and more potent anti-angiogenesis activity, should be approved soon. 
With the increase of population longevity, AMD incidence and prevalence will most 
probably increase, and these therapies may reduce both the societal and individual 
treatment burden. Although they are in the earlier clinical trial phases, the authors 
consider that the cell-based therapies for dry AMD and gene therapy for wet AMD 
are the more promising therapies for the future because they tend to correct the 
source’s problem. The new COVID vaccines also represent a significant step in this 
area, and these novel technologies may be future treatments for many other diseases.
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